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Summary 
Objectives: Sentinel lymph node biopsy (SLNB) is standard of care for staging 
regional LN in AJCC stage IB-IIC melanoma; using dual localization with 
radiolabelled colloid and blue dye. Combining these gives optimal accuracy; 
drawbacks include cumulative radiation exposure for healthcare workers, 
coordination between disciplines and anaphylaxis. An alternative tracer agent is 
indocyanine green (ICG); an optical enhancer that fluoresces in the near infrared 
range. This prospective cohort study assesses the feasibility of using ICG as a tracer 
agent to detect SLN in cutaneous melanoma. 
Methods: Primary melanoma patients diagnosed with pT1b-pT4b tumours 
undergoing SLNB were recruited over a 6-month period at a tertiary referral centre. 
All underwent standard preoperative lymphoscintigraphy (LSG) using 20-40MBq of 
Tc
99
radiolabelled nanocolloid plus intraoperative Patent Blue dye (PBD). ICG was 
administered as a third tracer agent intraoperatively. 
Results: 62 patients (33M/29F) were recruited; median age was 61 years. Median 
melanoma Breslow thickness was 1.6mm. 144 specimens containing 135 SLN were 
excised. Concordance rate for all 3 tracer agents was 88.1%(119/135 LN); that for 
radioisotope/PBD was 88.2%(95%CI:82.2,93.7). There were no discordance pairs 
between radioisotope/PBD compared to radioisotope/PBD/ICG. Radioisotope/ICG 
significantly increased the sensitivity of detecting SLN to 98.5%(95%CI:94.8,99.8); 
p<0.00001 compared to radioisotope/PBD. Concordance rate of intraoperative ICG 
drainage pattern with LSG was 22.6%. 
Conclusion: ICG utilization showed comparable sensitivity with gold standard. 
Technical challenges e.g. ICG leakage into biopsy field, poor concordance with LSG 
limits its efficacy in melanoma SLNB. We therefore do not recommend replacing 
current practice with ICG alone or by using a combination with TC
99
. 
Keywords: cutaneous melanoma; sentinel lymph node biopsy; indocyanine green 
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Sentinel lymph node biopsy (SLNB) is the standard of care for staging regional lymph 
nodes (LN) in stage AJCC IB-IIC melanoma 
1
. The technique utilises dual 
localisation with a radiolabelled colloid and a blue dye such as Patent Blue (PB). 
Combining these give an excellent sensitivity and specificity 
2,3
 
Potential drawbacks associated with the use of radioisotopes as tracer agents for 
localisation of SLN.  include cumulative radiation exposure for healthcare workers, 
problems with surgical waste disposal and potential repeat of the 2009 European 
shortage of radioisotopes.  Furthermore, co-ordinated efforts between different 
disciplines is essential. 
4
. Adverse events associated with the blue dye include 
prolonged skin-staining and anaphylaxis
5-7
. Localisation techniques using another 
non-radioactive tracer which has comparable accuracy to PB and Tc
99
 therefore 
warrants investigation. 
A potential alternative is inodcynanine green (ICG). Potential benefits include the 
absence of serious adverse reactions, (allergic reactions are rare
8
).  ICG is utilised as 
an optical enhancer and fluoresces light in the near-infrared range. It also emits 
fluorescence when it makes contact with plasma proteins in the lymphovascular 
systems of the extracellular compartment. 
The principle of fluorescence imaging has been applied to SLN mapping in early 
breast cancer The advantage of using ICG in these cancer types is that their lymphatic 
drainage is relatively predictable, often obviating the need for pre-operative LSG. In 
contrast, lymphatic drainage of cutaneous melanoma is notoriously unpredictable
15
 
necessitating the need for LSG to determine SLN location and potential nodal fields. 
Preliminary work with melanoma have been published, but with only a limited 
number of patients 
16-18
. 
The primary aim of this study was to assess the feasibility of utilising ICG to detect 
SLN in cutaneous melanoma; we aimed to achieve this by determining the sensitivity 
of ICG fluorescence imaging in SLN identification when combined with Tc
99 
and PB. 
Secondary endpoints included evaluation the accuracy of percutaneous visualisation 
of lymphatic channels and nodal fields intra-operatively compared to pre-operative 
LSG. Standard patient demographics and tumour characteristics were also collected. 
Primary cutaneous melanoma patients over the age of 18 years diagnosed with pT1b-
pT4b tumours, clinically N0, undergoing wide local excision and SLNB were 
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identified at specialist skin MDT and recruited in a prospective and consecutive 
manner over a 6-month period at a tertiary melanoma referral centre. Exclusion 
criteria included prior LN surgery, previous history of cutaneous melanoma, failed 
pre-operative LSG and contraindication to ICG such as pregnancy, lactating patients 
and those with thyroid problems. 
All patients underwent standard pre-operative LSG using 20-40 MBq of Tc-99-
radiolabelled nanocolloid (ELUMATIC III) in addition to intra-operative PB (Bleu 
Patente®; Guerbet)
18
. ICG was administered as a third tracer agent intra-operatively. 
 
This study protocol was approved by the Research Ethics Committee and MHRA 
(Eudra CT number: 2012-002244-25). 
 
62 patients (33M:29F) were recruited with a median age of 61 years (31-78 years). 
The distribution of melanoma and LN drainage characteristics are described in table 1. 
Median melanoma Breslow thickness was 1.6mm. None of the patients experienced 
anaphylaxis. 
144 specimens were excised, average 2.3 specimens per patient. 135 SLN were 
included in the histological analysis. The concordance rate for all 3 tracer agents was 
88.1% (119 of 135 LNs - table 2). The concordance rate between radio-isotope and 
PB was 88.2% (95% CI: 82.2%-93.7%). There were no discordant pairs between 
radio-isotope/PB compared to radio-isotope/PB/ICG fluorescence. One extra LN 
demonstrated fluorescence and blue staining only. All positive SLN were radioactive, 
blue and fluorescent (n=19). 
Radio-isotope and ICG fluorescence significantly increased the sensitivity of 
detecting SLN to 98.5% (95% CI: 94.8%-99.8%; p<0.00001) compared to radio-
isotope or PB alone. 
In 98.4% (61/62) of patients, lymphatic channels were visualised prior to incision 
using ICG. In 38 patients (62.3%), percutaneous visualisation with PDE showed 
greater detail or extra channels when compared against pre-operative LSG. However 
in 10 cases (16.1%), less details or less channels were visualised with PDE ;this 
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would have translated to missing a lymphatic drainage basin in 3 cases. Percutaneous 
LN visualisation was variably dependent on the depth of LN beneath the skin, 
however this was not consistent when compared to different LN drainage sites. 
 
 
According to our data, sensitivity of ICG with PB was 88.9%, which is lower than 
gold standard 
3,19
. Moreover, there is a level of inaccuracy when interpreting ICG; 
only 22.6% of patients had exact corresponding lymphatic channel imaging when 
comparing PDE and pre-operative LSG. This is likely due to the high variability of 
lymphatic drainage in melanoma 
15,20
, and thus a challenge when using ICG. 
Of our cohort, only 14.5% (n=9) patients presented with a head and neck (H&N) 
primary melanoma; however this translated to a quarter of the LN drainage basin. It is 
difficult to conclude wthether ICG would contribute a better operative achievement in 
H&N melanoma. 
PB alone only identified 120 of 135 SLNs (88.9% sensitivity)which correlates with 
data on development of dual technique
2,3
. Although the data suggests PB adds very 
little to the SLNB technique combined with Tc
99
 or ICG, practically it may aid the 
surgeon in SLN visualisation intra-operatively. Interestingly, radio-sensitive and 
positive fluorescence alone identified all but one SLN with a sensitivity of 98.5%; 
however utilisation of ICG was associated with some technical problemsPoor 
visualisation of lymphatic channels using ICG pre-operatively in obese patients makes 
it challenging to plan incisions. This is in keeping with studies that have found that 
when SLNs located deeper, such as the axilla or inguinal region, there is unreliable 
tracking percutaneously using fluorescence 
21,22
. 
Other tracer agents such as Tc-99m Tilmanocept (Lymphoseek®; Navidea) have been 
trialled in two near-identical non-randomised phase III trials that compared it to blue 
dye. Results have shown that it identifies 98.7% of blue nodes 
23
. This shows 
promising results for an alternate tracer agent. Other studies have investigated the use 
of hybrid radioactive and fluorescent tracer (ICG-
99m
Tc-nanocolloid in SLNB for 
H&N malignancies with favourable results 
24,25
; however further studies  are required 
to establish its use in melanoma outside the H&N region. 
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In this successful feasibility study, we have demonstrated that ICG, in combination 
with Tc
99
 radio-labelled nanocolloid has excellent sensitivity (98.5%) in detecting 
SLN in melanoma. However, in practice, the requirement for additional equipment, 
the relatively impracticality of being unable to follow the fluorescent imaging whilst 
using standard operating lights severely limits its application. Whilst we have 
identified some positive aspects to the technique, replacement of Tc
99
 or PB with ICG 
in SLNB for cutaneous melanoma is not recommended and we suggest that further 
developmental work is required. 
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Table 1: Melanoma and lymph node characteristics of cohort 
 Number (n) Percentage (%) 
Melanoma staging 
pT1b 14 22.6 
pT2a 24 38.7 
pT2b 3 4.9 
pT3b 7 11.3 
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pT4a 4 6.5 
pT4b 3 3.9 
Unknown 1 1.6 
Site of primary tumour 
Head and neck 9 14.5 
Trunk 28 45.2 
Limb 25 40.3 
Ulceration 
Present 15 24.2 
Absent 46 74.2 
Unknown 1 1.6 
Perineural invasion 
Present 1 1.6 
Absent 60 96.8 
Unknown 1 1.6 
Lymphovascular invasion 
Present 1 1.6 
Absent 56 90.3 
Possible 4 6.5 
Unknown 1 1.6 
Lymph node drainage basin 
Axilla 70 50 
Neck 37 26.4 
Groin 26 18.6 
Interval 7 5 
Number of drainage basins 
1 44 71 
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2 15 24.2 
3 2 3.2 
4 1 1.6 
Number of lymph nodes 
1 17 27.4 
2 22 35.4 
3 16 25.8 
4 4 6.5 
5 3 4.8 
 
Table 2: Sensitivity of tracer agents in the detection of SLN. 135 SLN excised in total. 
Tracer agent SLN detected Sensitivity 
 
95% CI Significance: 
McNemar’s test 
(vs. 
radioisotope/ICG) 
Radio/PB/ICG 119 88.2% (82.2% -93.7%) p=1.0000 
Radio/PB 119 88.2% (82.2% - 93.7%) Reference 
ICG/PB 120 88.9% (82.3% - 93.7%) p=1.0000 
Radio/ICG 133 98.5% (94.8 % - 99.8%) p<0.0001 
Radio 134 99.3% (95.9% - 100%) p<0.0001 
PB 134 99.3% (95.9% - 100%) p<0.0001 
ICG 120 88.9% (82.3% - 93.7%) p=1.0000 
SLN – sentinel lymph node, Radio – radioisotope, PB – Patent Blue, ICG – indocyanine green, 
CI – confidence interval 
